Archive

HIGHLIGHTS

 
LSP raises record €750 million in 10 months for life sciences innovations
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA OR ANY JURISDICTION IN WHICH TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION   Succe[...]
 
LSP leads $28 million financing in Lumeon
Amsterdam, the Netherlands, December 4, 2018 – LSP, one of Europe’s leading life sciences and healthcare investors, today announced its investment in Lumeon, a digital health company and leader in the field of[...]
 
LSP wins Lifestars Award for EU investment firm of the year
Celebrating success across life sciences   Amsterdam, The Netherlands, November 14, 2018 – LSP is pleased to announce that it has been recognised as the winner of the EU Investment Firm of the year at the 2[...]
 
LSP leads $45 million Series D Financing in Endotronix
Amsterdam, the Netherlands, September 17, 2018 – LSP, Europe’s leading life sciences investor, today announced its investment in Endotronix, Inc., a digital health, medtech company dedicated to advancing the treat[...]
 
LSP co-leads $85 million (£65 million) Series B Financing in Artios Pharma
LSP returns to support the former KuDOS team that successfully developed the first PARP inhibitor Olaparib   Amsterdam, The Netherlands, August 10, 2018 – LSP, Europe’s leading life sciences investor, tod[...]
 
Her Majesty Queen Máxima launches Oncode Institute, founded by LSP's Rudy Dekeyser and René Kuijten
Oncode Institute combines 600 of the very best oncology researchers with a highly qualified valorisation staff to ensure that breakthrough discoveries get to patients faster.    The origins of Oncode go back[...]
 
LSP reaches milestone: 10 years investing in listed Life Sciences Securities
LSP Life Sciences Fund generates net return of 39% in 2017   Amsterdam, January 16 2018 - LSP, the European life sciences investment group, today announced it has reached its 10 year milestone investing in li[...]
 
LSP Raises EUR 280 Million to Invest In Healthcare Innovation
Largest fund in Europe dedicated to medical technology Significant fundraise reflects successful investment strategy to achieve better care at lower costs   Amsterdam, 12 December 2017 – LSP, the Europe[...]
 
Marco Groot over LSP in het FD
Amsterdam, April 11, 2017 Marco Groot over LSP in het FD Lees de gehele column: Een absoluut beter resultaat   Amsterdam, July 11, 2017: Marco Groot blikt in het FD terug op zijn eerdere positiev[...]
 
LSP RECOMMENDS
LSP Partner Clemens van Blitterswijk gives a TedX on the future of regenerative medicine
 
De Telegraaf: gespreid in biotech en profiteren van overnames via LSP
Lees de gehele column: gespreid in biotech en profiteren van overnames via LSP
 
BioCentury: LSP's Four of a Kind
To read the full article click here
 
Is a cure for cancer finally within reach?
To read the full article click here

2018


Kuros announces final result of capital increase – total gross proceeds of 16.1 million raised
Schlieren (Zurich), Switzerland, December 13, 2018 – Kuros Biosciences (SIX: KURN) (the Company or Kuros) announces the final number of offered shares and gross proceeds from the rights offering and share placement, [...]
Kuros announces results of rights offering – capital increase will be implemented
Schlieren (Zurich), Switzerland, December 12, 2018 – Kuros Biosciences (SIX: KURN) (the Company or Kuros) announces the results of the rights offering, first announced on November 29, 2018, in which a total of 8,013 [...]
Aelin Therapeutics pursues new cancer drugs
The young biotech spin-off gains momentum with a VLAIO grant and an investor award   Leuven, December 12, 2018 - Aelin Therapeutics announced today that it has been awarded close to 1M EUR in non-dilutive fund [...]
Orphazyme expects to announce results of full data set for Niemann-Pick disease Type C (NPC) Phase II/III trial in Q1 2019
Copenhagen, December 10, 2018 – Orphazyme A/S, a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced that the Company expects to announce the results [...]
LSP co-leads $17 Million Series A financing in XyloCor Therapeutics to advance gene therapy in cardiovascular disease
Novel gene therapy for patients with treatment-resistant angina who have no remaining treatment options is ready to enter clinical development Pharmaceutical industry veteran and former GSK executive Al Gian [...]
LSP leads $28 million financing in Lumeon
Amsterdam, the Netherlands, December 4, 2018 – LSP, one of Europe’s leading life sciences and healthcare investors, today announced its investment in Lumeon, a digital health company and leader in the field of [...]


2018
2017
2016
2015
2014
2013
2012
back to news overview
Follow us

Archive

HIGHLIGHTS

 
LSP raises record €750 million in 10 months for life sciences innovations
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA OR ANY JURISDICTION IN WHICH TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION   Succe[...]
 
LSP leads $28 million financing in Lumeon
Amsterdam, the Netherlands, December 4, 2018 – LSP, one of Europe’s leading life sciences and healthcare investors, today announced its investment in Lumeon, a digital health company and leader in the field of[...]
 
LSP wins Lifestars Award for EU investment firm of the year
Celebrating success across life sciences   Amsterdam, The Netherlands, November 14, 2018 – LSP is pleased to announce that it has been recognised as the winner of the EU Investment Firm of the year at the 2[...]
 
LSP leads $45 million Series D Financing in Endotronix
Amsterdam, the Netherlands, September 17, 2018 – LSP, Europe’s leading life sciences investor, today announced its investment in Endotronix, Inc., a digital health, medtech company dedicated to advancing the treat[...]
 
LSP co-leads $85 million (£65 million) Series B Financing in Artios Pharma
LSP returns to support the former KuDOS team that successfully developed the first PARP inhibitor Olaparib   Amsterdam, The Netherlands, August 10, 2018 – LSP, Europe’s leading life sciences investor, tod[...]
 
Her Majesty Queen Máxima launches Oncode Institute, founded by LSP's Rudy Dekeyser and René Kuijten
Oncode Institute combines 600 of the very best oncology researchers with a highly qualified valorisation staff to ensure that breakthrough discoveries get to patients faster.    The origins of Oncode go back[...]
 
LSP reaches milestone: 10 years investing in listed Life Sciences Securities
LSP Life Sciences Fund generates net return of 39% in 2017   Amsterdam, January 16 2018 - LSP, the European life sciences investment group, today announced it has reached its 10 year milestone investing in li[...]
 
LSP Raises EUR 280 Million to Invest In Healthcare Innovation
Largest fund in Europe dedicated to medical technology Significant fundraise reflects successful investment strategy to achieve better care at lower costs   Amsterdam, 12 December 2017 – LSP, the Europe[...]
 
Marco Groot over LSP in het FD
Amsterdam, April 11, 2017 Marco Groot over LSP in het FD Lees de gehele column: Een absoluut beter resultaat   Amsterdam, July 11, 2017: Marco Groot blikt in het FD terug op zijn eerdere positiev[...]
 
LSP RECOMMENDS
LSP Partner Clemens van Blitterswijk gives a TedX on the future of regenerative medicine
 
De Telegraaf: gespreid in biotech en profiteren van overnames via LSP
Lees de gehele column: gespreid in biotech en profiteren van overnames via LSP
 
BioCentury: LSP's Four of a Kind
To read the full article click here
 
Is a cure for cancer finally within reach?
To read the full article click here

2018


Kuros announces final result of capital increase – total gross proceeds of 16.1 million raised
Schlieren (Zurich), Switzerland, December 13, 2018 – Kuros Biosciences (SIX: KURN) (the Company or Kuros) announces the final number of offered shares and gross proceeds from the rights offering and share placement, [...]
Kuros announces results of rights offering – capital increase will be implemented
Schlieren (Zurich), Switzerland, December 12, 2018 – Kuros Biosciences (SIX: KURN) (the Company or Kuros) announces the results of the rights offering, first announced on November 29, 2018, in which a total of 8,013 [...]
Aelin Therapeutics pursues new cancer drugs
The young biotech spin-off gains momentum with a VLAIO grant and an investor award   Leuven, December 12, 2018 - Aelin Therapeutics announced today that it has been awarded close to 1M EUR in non-dilutive fund [...]
Orphazyme expects to announce results of full data set for Niemann-Pick disease Type C (NPC) Phase II/III trial in Q1 2019
Copenhagen, December 10, 2018 – Orphazyme A/S, a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced that the Company expects to announce the results [...]
LSP co-leads $17 Million Series A financing in XyloCor Therapeutics to advance gene therapy in cardiovascular disease
Novel gene therapy for patients with treatment-resistant angina who have no remaining treatment options is ready to enter clinical development Pharmaceutical industry veteran and former GSK executive Al Gian [...]
LSP leads $28 million financing in Lumeon
Amsterdam, the Netherlands, December 4, 2018 – LSP, one of Europe’s leading life sciences and healthcare investors, today announced its investment in Lumeon, a digital health company and leader in the field of [...]


2018
2017
2016
2015
2014
2013
2012
back to news overview